Aspiring Ventures’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$306K Buy
255
+9
+4% +$9.2K 0.07% 63
2026
Q1
$226K Sell
246
-46
-16% -$46.6K 0.07% 72
2025
Q4
$314K Buy
292
+16
+6% +$15.3K 0.11% 56
2025
Q3
$211K Sell
276
-71
-20% -$52.8K 0.07% 63
2025
Q2
$270K Sell
347
-7
-2% -$5.44K 0.12% 54
2025
Q1
$275K Buy
354
+3
+0.9% +$2.5K 0.15% 43
2024
Q4
$255K Buy
+351
New +$291K 0.16% 41

Other funds holding LLY

Aspiring Ventures's LLY Position: Q2 2026 in Review

Aspiring Ventures increased its Eli Lilly (LLY) stake by 3.7% in Q2 2026, buying an estimated $9.2K and bringing the position to 255 shares worth $306K. The position accounts for 0.07% of the portfolio, ranked #63.

Aspiring Ventures first reported a position in LLY in Q4 2024 and has held it in 7 quarters since. The position peaked at $314K in Q4 2025. 4,630 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Aspiring Ventures held 255 shares of Eli Lilly worth $306K as of Q2 2026.
  • Aspiring Ventures bought 9 Eli Lilly shares in Q2 2026, an estimated $9.2K.
  • Eli Lilly made up 0.07% of Aspiring Ventures's portfolio in Q2 2026, its #63 holding.
  • Aspiring Ventures first reported a position in Eli Lilly in Q4 2024 and has held it in 7 quarters since.
  • Aspiring Ventures's Eli Lilly position peaked at $314K in Q4 2025.
  • 4,630 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Aspiring Ventures's 13F filing for Q2 2026, filed 5 Aug 2026.